Pathogenesis of pulmonary hypertension: A case for caveolin-1 and cell membrane integrity

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 306, Issue 1, 2014, Pages

  Mathew, Rajamma ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Caveolin 1; Endothelial cells; Pulmonary hypertension; Smooth muscle cells

Indexed keywords

CAVEOLIN 1;

CAVEOLA; CELL DAMAGE; CELL FUNCTION; CELL MEMBRANE; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

EID: 84891550343     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00266.2013     Document Type: Review

References (137)

1. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121: 2747-2754, 2010.
2. Achcar RO, Demura Y, Rai PR, Taraseviciene-Stewart L, Kasper M, Voelkel NF, Cool CD. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 129: 696-705, 2006.
3. Adebiyi A, Narayanan D, Jaggar JH. Caveolin-1 assembles type 1 inositol 1,4,5-triphosphate receptors and canonical transient receptor potential 3 channels into a functional signaling complex in arterial smooth muscle cells. J Biol Chem 286: 4341-4348, 2010.
4. Annabi B, Lachambre M, Bousquet-Gagnon N, Pagé M, Gingras D, Béliveau R. Localization of membrane type 1 metalloproteinase in caveolae membrane domains. Biochem J 353: 547-553, 2001.
5. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenic protein receptor. Circulation 105: 1672-1678, 2002.
6. Austin ED, Ma L, Le Duc C, Berman-Rozenzweig E, Borczuk A, Phillips JA 3rd, Palomero T, Sumazin P, Kim HR, Talati MH, West J, Loyd JE, Chung WK. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 5: 336-343, 2012.
7. Balabanian K, Foussat A, Dorfmüller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol AC, Simonneau G, Emilie D, Humbert M. CX3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 1419-1425, 2002.
8. Balcells M, Martorell J, Olivé C, Santacana M, Chitalia V, Cardoso AA, Edelman ER. Smooth muscle cells orchestrate the endothelial cells response to flow and injury. Circulation 121: 2192-2199, 2010.
9. Becker BF, Chappell D, Brueger D, Annecke T, Jacob M. Therapeutic strategies targeting the endothelial gycocalyx: acute deficits, but great potential. Cardiovasc Res 87: 300-310, 2010.
10. Berger RM, Geiger R, Hess J, Bogers AJ, Mooi WJ. Altered arterial expression patterns of inducible and endothelial nitric oxide synthase in pulmonary plexogenic arteriopathy caused by congenital heart disease. Am J Respir Crit Care Med 163: 1493-1499, 2001.
11. Bhargava A, Kumar A, Yuan N, Gewitz MH, Mathew R. Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Dis 1: 126-132, 1999.
12. Billaud M, Marthan R, Savineau JP, Guibert C. Vascular smooth muscle modulates endothelial control of vasoreactivity via reactive oxygen species production through myoendothelial communications. PLoS One 4: e6432, 2009.
13. Bonor J, Adams EL, Bragdon B, Morcychuk O, Czymmek KJ, Nohe A. Initiation of BMP2 signaling domains in plasma membrane. J Cell Physiol 227: 2880-2888, 2012.
14. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 169: 764-769, 2004.
15. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin 6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3 micro RNA cluster 17/29 pathway. Circ Res 104: 1184-1191, 2009.
16. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, Sessa WC. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6: 1362-1367, 2000.
17. Burke DL, Frid MG, Kunrath CL, Karoor V, Anwar A, Wagner BD, Strassheim D, Stenmark KR. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol 297: L238-L250, 2009.
18. Chen CA, Druhan LJ, Varadharaj S, Chen YR, Zweiler JL. Phosphorylation of endothelial nitric-oxide synthase regulates superoxide formation from the enzyme. J Biol Chem 283: 27038-27047, 2008.
19. Chow AK, Cena J, El-Yazbi AF, Crawford BD, Holt A, Cho WJ, Daniel EE, Schulz R. Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J Mol Cell Cardiol 42: 896-901, 2007.
20. Chun M, Liyanage UK, Lisanti MP, Lodish HF. Signal transduction of a G protein-coupled receptor in caveolae: colocalization of endothelin and its receptor with caveolin. Proc Natl Acad Sci USA 91: 11728-11732, 1994.
21. Cicalini S, Almodovar S, Grilli E, Flores S. Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect 17: 25-33, 2011.
22. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP. Identification of peptide and protein ligands for caveolin-scaffolding domain: implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 272: 6525-6533, 1997.
23. D'Alonzo GE, Barst RJ, Ayers SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW, Wu M. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349, 1991.
24. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-beta internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rhematol 20: 713-719, 2008.
25. Dereddy N, Huang J, Erb M, Guzel S, Wolk JH, Sett SS, Gewitz MH, Mathew R. Associated inflammation or increased flow-mediated shear stress, but not the pressure alone, disrupts endothelial caveolin-1 in infants with pulmonary hypertension. Pulm Circ 2: 492-500, 2012.
26. Dorfmüller P, Zarka V, Durand-Gasselin J, Monti G, Balabanian K, Garcia G, Capron F, Coulomb-Lherminé A, Marfaing-Koka A, Simonneau G, Emilie D, Humbert M. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 534-539, 2002.
27. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452, 2001.
28. Dreja K, Voldstedlund M, Vinten J, Tranum-Jensen J, Hellstrand P, Swärd K. Cholesterol depletion disrupts caveolae and differentially impairs agonist-induced arterial contraction. Arterioscler Thromb Vasc Biol 22: 1267-1272, 2002.
29. Engelman JA, Zhang XL, Razani B, Pestell RG, Lisanti MP. p42/44 MAP kinase-dependent and independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascade transcriptionally downregulates caveolin-1 promotor activity. J Biol Chem 274: 32333-32341, 1999.
30. Fishman AP. Primary pulmonary hypertension: a look back. J Am Coll Cardiol 43, Suppl 12: 2S-4S, 2004.
31. Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae and endothelial function. Arterioscler Thromb Vasc Biol 23: 1161-1168, 2003.
32. Fujimoto T. Calcium pump of the plasma membrane is localized in caveolae. J Cell Biol 120: 1147-1157, 1993.
33. Galbiati F, Volonté D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactive p42/44 MAP kinase cascade. EMBO J 17: 6633-6648, 1998.
34. Galbiati F, Volonté D, Liu J, Capozza F, Frank PG, Zhu L, Pestell RG, Lisanti MP. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol Biol Cell 12: 2229-2244, 2001.
35. Gao LF, Wen LJ, Yu H, Zhang L, Meng Y, Shao YT, Xu DQ, Zhao XJ. Knockdown of Stat3 expression using RNAi inhibits growth of laryngeal tumors in vivo. Acta Pharmacol Sin 27: 347-352, 2006.
36. Gao L, Lipowski HH. Composition of the endothelial glycocalyx and its relation to its thickness and diffusion of small solutes. Microvasc Res 80: 394-401, 2010.
37. Geiger R, Berger RM, Hess J, Bogers AJ, Sharma HS, Mooi WJ. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol 191: 202-207, 2000.
38. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, Voelkel NF. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene micoarray analysis. Circ Res 88: 555-562, 2001.
39. Grange DN, Senchenkova E. Inflammation and microcirculation. Integrated system physiology: from cell to function. San Rafael, CA: Morgan Claypool Life Sciences, 2010.
40. Gratton JP, Fontana J, O'Connor DS, Garcia-Cardena G, McCabe TJ, Sessa WC. Reconstitution of an endothelial nitric oxide synthase (eNOS), hsp90 and caveolin-1 complex in vitro: Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS ffrom caveolin-1. J Biol Chem 275: 22268-22277, 2000.
41. Hagen M, Fagan K, Steudel W, Carr M, Lane K, Rodman DM, West J. Interaction of interleukin-6 and BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 292: L1473-L1479, 2007.
42. Hassan GS, Williams TM, Frank PG, Lisanti MP. Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal transduction. Am J Physiol Heart Circ Physiol 290: H2393-H2401, 2006.
43. Hassan GS, Jasmin JF, Schubert W, Frank PG, Lisanti MP. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry 43: 8312-8321, 2004.
44. Hirai T, Masaki T, Kuratsune M, Yorioka N, Kohno N. PDGF receptor tyrosine kinase inhibitor suppresses measngial cell proliferation involving STAT3 activation. Clin Exp Immunol 144: 353-361, 2006.
45. Hirose S, Hosoda Y, Furuya S, Otsuki T, Ikeda E. Expression of vascular endothelial growth factor and receptors correlates closely with formation of plexiform lesion in human pulmonary hypertension. Pathol Int 50: 472-479, 2000.
46. Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M, Marcos E, Tissot CM, Dubois-Randé JL, Amsellem V, Adnot S. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am Respir Cell Mol Biol 48: 568-577, 2013.
47. Huang J, Kaminski PM, Edwards JG, Yeh A, Wolin MS, Frishman WH, Gewitz MH, Mathew R. Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol 294: L1250-L1259, 2008.
48. Huang J, Wolk J, Gewitz MH, Mathew R. Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension. Exp Lung Res 36: 57-66, 2010.
49. Huang J, Wolk JH, Gewitz MH, Mathew R. Caveolin-1 expression during the progression of pulmonary hypertension. Exp Biol Med (Maywood) 237: 956-965, 2012.
50. Huber LC, Soltermann A, Fischler M, Gay S, Weder W, Russi EW, Speich R, Ulrich S. Caveolin-1 expression and hemodynamics in COPD patients. Open Respir Med J 3: 73-78, 2009.
51. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151: 1628-1631, 1995.
52. Humbert M, Sitbbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Wietzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R, Simonneau G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in modern management era. Circulation 122: 156-163, 2010.
53. 2+ and inositol 1, 4, 5-triphosphate mediated signaling across myoendothelail junction. Circ Res 100: 246-254, 2007.
54. Isshiki M, Ying YS, Fujita T, Anderson RG. A molecular sensor detects signal transduction from caveolae in living cells. J Biol Chem 277: 43389-43398, 2002.
55. 2+-dependent signal transduction. Traffic 4: 717-723, 2003.
56. Itoh T, Nagaya N, Ishibashi-Ueda H, Kyotani S, Oya H, Sakamaki Kimura H, Nakanishi N. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 11: 158-163, 2006.
57. Jaffe EA, Grulich J, Weksler BB, Hampel G, Watanabe K. Correlation between thrombin-induced prostacyclin production and inositol triphosphate and cytolsolic free calcium levels in cultured human endothelial cells. J Biol Chem 262: 8557-8565, 1987.
58. Jasmin JF, Mercier I, Hnasko R, Cheung MW, Tanowitz HB, Dupuis R, Lisanti MP. Lung remodeling in pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovasc Res 63: 747-755, 2004.
59. Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. Shortterm administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 114: 912-920, 2006.
60. Jasmin JF, Mercier I, Sotgia F, Lisanti MP. SOCS proteins and caveolin-1 as negative regulators of endocrine signaling. Trends Endocrinol Metab 17: 150-158, 2006.
61. Karuppiah K, Druhan LJ, Chen CA, Smith T, Zweier JL, Sessa WC, Cardounel AJ. Suppression of eNOS-derived superoxide by caveolin-1:a biopterin-dependent mechanism. Am J Physiol Heart Circ Physiol 301: H903-H911, 2011.
62. Kawabe J, Okumura S, Lee MC, Sadoshima J, Ishikawa Y. Translocation of caveolin regulates stretch-induced ERK activity in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 286: H1845-H1852, 2004.
63. Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, Koseki T, Nishihara T, Ikeda Y. Bone Morphogenic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 96: 2005-2011, 2000.
64. Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosenzweig EB, Barst RJ. Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 128: 2355-2362, 2005.
65. Kolosionek E, Graham BB, Tuder RM, Butrous G. Pulmonary vascular disease associated with parasitic infection-the role of schistosomiasis. Clin Microbiol Infect 17: 15-24, 2011.
66. Kümpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, Olsson KM, Jonigk D, Maegel L, Bockmeyer CL, David S, Hoeper MM. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 31: 2291-2300, 2010.
67. Kurzchalia TV, Dupree P, Parton RG, Kellner R, Virta H, Lehnert M, Simons K. VIP21, a 21 kD membrane protein is an integral component of trans-golgi-network-derived transport vescicles. J Cell Biol 118: 1003-1014, 1992.
68. Labreque L, Royal I, Surprenant DS, Patterson C, Gingras D, Béliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane. Mol Biol Cell 14: 334-347, 2003.
69. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D'Ortho MP, Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 25: 834-842, 2005.
70. Lesprit P, Godeau B, Authier FJ, Soubrier M, Zuber M, Larroche C, Viard JP, Wechsler B, Gherardi R. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 157: 907-911, 1998.
71. Liu J, Razani B, Tang S, Terman BI, Ware JA, Lisanti MP. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. J Biol Chem 274: 15781-15785, 1999.
72. Mason NA, Springall DR, Burke M, Pollock J, Mikhail G, Yacoub MH, Polak JM. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol 185: 313-318, 1998.
73. Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, Vasanji A, Drazba J, Anand-Apte B, Erzurum SC. Hyperproliferative apoptosisresistant endothelial cells in idiopathic pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol 293: L548-L554, 2007.
74. Mathai SC, Hassoun PM. Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev Respir Med 5: 267-279, 2011.
75. Mathew R, Zeballos GA, Tun H, Gewitz MH. Role of nitric oxide and endothelin 1 imbalance in monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res 30: 739-746, 1995.
76. Mathew R, Yuan N, Rosenfeld L, Gewitz MH, Kumar A. Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs. Heart Dis 4: 152-158, 2002.
77. Mathew R, Huang J, Shah M, Patel K, Gewitz M, Sehgal PB. Disruption of endothelial-cell caveolin-1α/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 110: 1499-1506, 2004.
78. Mathew R, Huang J, Gewitz MH. Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective. Cardiol Rev 15: 143-149, 2007.
79. Mathew R, Huang J, Katta US, Krishnan U, Sandoval C, Gewitz MH. Immunosuppressant-induced endothelial damage and pulmonary arterial hypertension. J Pediatr Hematol Oncol 33: 55-58, 2011.
80. Mathew R. Cell-specific dual role of caveolin-1 in pulmonary hypertension. Pulm Med 2011: 573432, 2011.
81. Mathew R. Pulmonary hypertension: endothelial cell function. In: Pulmonary Hypertension: from Bench Research to Clinical Challenges, edited by Sulica R. and Preston I. Rijeka, Croatia: Intech, 2011, p. 1-24; doi:10.5772/26198.
82. Mathew R. PDGF receptor blocker for pulmonary hypertension: a new agent in therapeutic arsenal. Expert Opin Investig Drugs 21: 139-142, 2012.
83. Metcalf DJ, Nightingale TD, Zenner H, Liu-Roberts WW, Cutler DF. Formation and function of Weibel Palade bodies. J Cell Sci 121: 19-27, 2008.
84. Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB. Caveolin-1 regulation of endothelial cells. Am J Physiol Lung Cell Mol Physiol 285: L1179-L1183, 2003.
85. Murakami K, Mathew R, Huang J, Farahami R, Peng H, Olson SC, Etlinger JD. Smurf-1 ubiquitin ligase causes downregulation of BMP receptors and is induced in monocrotaline and hypoxia models of pulmonary arterial hypertension. Exp Biol Med (Maywood) 235: 805-813, 2010.
86. Murata T, Yamawaki H, Hori M, Sato K, Ozaki H, Karaki H. Hypoxia impairs endothelium-dependent relaxation in organ cultured pulmonary artery. Eur J Pharmacol 421: 45-53, 2001.
87. Murata T, Sato K, Hori M, Ozaki H, Karaki H. Decreased endothelial nitric oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem 277: 44085-44092, 2002.
88. Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, Ozaki H. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 25: 2335-2342, 2005.
89. Murata T, Lin MI, Huang Y, Yu J, Bauer PM, Giordano FG, Sessa WC. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med 204: 2373-2383, 2007.
90. Murata T, Lin MI, Stan RV, Bauer PM, Yu J, Sessa WC. Genetic evidence supporting caveolae microdomain regulation of calcium entry in endothelial cells. J Biol Chem 282: 16631-16643, 2007.
91. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 69: 614-624, 2006.
92. Nomura R, Fujimoto T. Tyrosine-phosphorylated caveolin-1: Immunolocalization and molecular characterization. Mol Biol Cell 10: 975-986, 1999.
93. Nunes H, Humbert M, Capron F, Brauner M, Sitbon O, Battesti JP, Simonneau G, Valeyre D. Pulmonary hypertension associated with sarcoidosis: mechanisms, hemodynamics and prognosis. Thorax 61: 68-74, 2006.
94. Okamoto T, Schlegel A, Scherer P, Lisanti MP. Caveolins, a family for organizing "preassembled signaling complex" at the plasma membrane. J Biol Chem 273: 5419-5422, 1998.
95. Ozaki M, Kawashima S, Yamashita T, Ohashi Y, Rikitake Y, Inoue N, Hirata KI, Hayashi Y, Itoh H, Yokoyama M. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension 37: 322-327, 2001.
96. Paffett ML, Naik JS, Riddle MA, Manicucci SD, Gonzales AJ, Resta TC, Walker BR. Altered membrane lipid domains limit pulmonary endothelial calcium entry following chronic hypoxia. Am J Physiol Heart Circ Physiol 301: H1331-H1340, 2011.
97. Palade GE. Fine structure of blood capillaries (Abstract). J Appl Phys 24: 1424-1436, 1953.
98. Patel HH, Zhang S, Murray F, Suda RY, Head BP, Yokoyama U, Swaney JS, Niesman IR, Schermuly RT, Pullamsetti SS, Thistlethwaite PA, Miyanohara A, Farquhar MG, Yuan JX, Insel PA. Increased smooth muscle expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB J 21: 2970-2979, 2007.
99. Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction of molecules. Annu Rev Pharmacol Toxicol 48: 359-391, 2008.
100. Perros F, Montani D, Dorfmüller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, Hervé P, Emilie D, Eddahibi S, Simonneau G, Souza R, Humbert M. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 81-88, 2008.
101. Peterson TE, Guicciardi ME, Gulati R, Kleppe LS, Mueske CS, Mookadam M, Sowa G, Gores GJ, Sessa WC, Simari RD. Caveolin-1 can regulate vascular smooth muscle cell fate by switching plateletderived growth factor from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol 23: 1521-1527, 2003.
102. Pogoriler JE, Rich S, Archer SL, Husain AN. Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology 61: 597-609, 2012.
103. Pritchard KA Jr, Ackerman AW, Gross ER, Stepp DW, Shi Y, Fontana JT, Baker JE, Sessa WC. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric oxide synthase. J Biol Chem 276: 17621-17624, 2001.
104. Ramos M, Lame MW, Segall HJ, Wilson DW. The BMP II receptor is located in lipid rafts, including caveolae of pulmonary endothelium in vivo and in vitro. Vascul Pharmacol 44: 50-59, 2006.
105. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001.
106. Reynolds AM, Xia W, Holmes MD, Hodge SJ, Danilov S, Curiel DT, Morrell NW, Reynolds PN. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 292: L1182-L1192, 2007.
107. Roberts KE, McElroy JJ, Wong WP, Yen E, Widlitz A, Barst RJ, Knowles JA, Morse JH. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 24: 371-374, 2004.
108. Rose SL, Babensee JE. Smooth muscle phenotype alters cocultured endothelial cell response to biomaterial-pretreated leukocytes. J Biomed Mater Res A 84: 661-671, 2008.
109. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell 68: 673-682, 1992.
110. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 19: 1178-1180, 2005.
111. Sakao S, Tarasviciene-Stewart L, Wood K, Cool CD, Voelkel NF. Apoptosis of pulmonary vascular endothelial cells stimulates vascular smooth muscle growth. Am J Physiol Lung Cell Mol Physiol 291: L362-L368, 2006.
112. 2+ signals and gap junction function are regulated by caveolin in endothelial cells. Circulation 117: 1065-1074, 2008.
113. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821, 2005.
114. Sedding DG, Braun-Dullaeus RC. Caveolin-1: dual role for proliferation of vascular smooth muscle cells. Trends Cardiovasc Med 16: 50-55, 2006.
115. Shibata R, Kai H, Seki Y, Kato S, Wada Y, Hanakawa Y, Hashimoto K, Yoshimura A, Imaizumi T. Inhibition of STAT3 prevents neointima formation by inhibiting proliferation and promoting apoptosis of neointimal smooth muscle cells. Hum Gene Ther 14: 601-610, 2003.
116. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated classification of pulmonary hypertension. J Am Coll Cardiol 54: S43-S54, 2009.
117. Sluiter I, van Heijst A, Haasdijk R, Kempen MB, Boerema-de Munck A, Reiss I, Tibboel D, Rottier RJ. Reversal of pulmonary vascular remodeling in pulmonary hypertensive rats. Exp Mol Pathol 93: 66-73, 2012.
118. Smadja DM, Guassem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S, Agnoletti G, Vouhé PR, Bonnet D, Lévy M. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 119: 374-381, 2009.
119. Smith P, Heath D. Electron microscopy of the plexiform lesion. Thorax 34: 177-186, 1979.
120. 2+ entry in endothelial cells. Am J Physiol Cell Physiol 296: C403-C413, 2009.
121. Tarbell JM. Shear stress and the endothelial transport barrier. Cardiovasc Res 87: 320-330, 2010.
122. ten Freyhaus H, Dagnell M, Leuchs M, Vantler M, Berghausen EM, Caglayan E, Weissmann N, Dahal BK, Schermuly RT, Ostman A, Kappert K, Rosenkranz S. Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by downregulation of protein tyrosine phosphatases. Am J Respir Crit Care Med 183: 1092-1102, 2011.
123. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPRII, a receptor member of the TGF-beta family. J Med Genet 37: 741-745, 2000.
124. Thyberg J. Differences in caveolae dynamics in vascular smooth muscle cells of different phenotypes. Lab Invest 80: 915-929, 2000.
125. Torres VA, Tapia JC, Rodríguez DA, Párraga M, Lisboa P, Montoya M, Leyton L, Quest AF. Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin. J Cell Sci 119: 1812-1823, 2006.
126. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275-285, 1994.
127. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM, Voelkel NF. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 195: 367-374, 2001.
128. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 42: 1163-1184, 1970.
129. Wagenvoort CA. Plexogenic arteriopathy. Thorax 49, Suppl: S39-S45, 1994.
130. Wertz JW, Bauer PM. Caveolin-1 regulates BMPRII localization and signaling in vascular smooth muscle cells. Biochem Biophys Res Comm 375: 557-561, 2008.
131. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, Cool CD, Taubman MB. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 293: L583-L590, 2007.
132. Wunderlich C, Schmeisser A, Heerwagen C, Ebner B, Schober K, Braun-Dullaeus RC, Schwenke C, Kasper M, Morawietz H, Strasser RH. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. Pulm Pharmacol Ther 21: 507-515, 2008.
133. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol 1: 445-458, 1955.
134. Yamamoto M, Toya Y, Jensen RA, Ishikawa Y. Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Exp Cell Res 247: 380-388, 1999.
135. Zhang XL, Topley N, Ito T, Phillips A. Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J Biol Chem 280: 12239-12245, 2005.
136. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J Jr, Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99: 11375-11380, 2002.
137. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, Brovkovych V, Yuan JX, Wharton J, Malik AB. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 119: 2009-2018, 2009.